Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shin Nippon Biomedical Laboratories to Tie Up with US CRO for Clinical Development Services
January 5, 2015
- Opdivo Receives Accelerated Approval in US for Malignant Melanoma: BMS
January 5, 2015
- Bayer Yakuhin Files PAH Drug Iloprost for Approval
December 26, 2014
- Sumitomo Dainippon Aims to File Lurasidone in Japan in FY2015 following Favorable Asian PIII Study Results
December 26, 2014
- Chugai Wins First Round in Patent Infringement Lawsuit for Oxarol Ointment
December 26, 2014
- Otsuka Obtains Rights from ARIAD to Develop, Commercialize Ponatinib in Japan and Other Asian Countries
December 26, 2014
- Taiho Completes NDA Submission for Lonsurf in US
December 26, 2014
- Takeda Files NDA for Glatiramer Licensed from Teva for Relapse Prevention of Multiple Sclerosis
December 26, 2014
- Astellas Expands Scope of Collaboration with Cytokinetics in Skeletal Muscular Disease Field
December 25, 2014
- NDA for Selexipag Filed in US by Actelion: Nippon Shinyaku
December 25, 2014
- Fujifilm Completes Acquisition of Kalon Biotherapeutics
December 24, 2014
- AZ, Quintiles Create New Drug Development Team, Fusing Pharma’s Expertise with CRO’s Knowhow
December 24, 2014
- Ono Licenses Exclusive Worldwide Rights for BTK Inhibitor to Gilead Excluding East and South East Asia
December 22, 2014
- Chugai, Yakult File Xeloda, Elplat for Postoperative Adjuvant Chemotherapy for Gastric Cancer
December 22, 2014
- Poteligeo Now Indicated for Chemotherapy-Naïve CCR4-Positive ATL: Kyowa Kirin
December 19, 2014
- Taiho’s Abraxane Gets Nod for Unresectable Pancreatic Cancer
December 19, 2014
- Takeda Names Sanofi’s Plump as New R&D Head
December 19, 2014
- MTPC Reorganizing Its US Affiliates to Accelerate Operation Expansion
December 19, 2014
- Fujifilm Holdings Makes J-TEC Its Consolidated Subsidiary
December 19, 2014
- Daiichi Sankyo Looks to Bring Annual 8-10 Projects into Clinical Phase, Open Innovation Key to Success: R&D Execs
December 18, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…